De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Amphastar Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Amphastar Pharmaceuticals' is Jack Zhang, benoemd in Jan1996, heeft een ambtstermijn van 28.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.72M, bestaande uit 11.6% salaris en 88.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.01% van de aandelen van het bedrijf, ter waarde $ 118.31M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 10.9 jaar en 5.3 jaar.
Belangrijke informatie
Jack Zhang
Algemeen directeur
US$7.7m
Totale compensatie
| Percentage CEO-salaris | 11.6% |
| Dienstverband CEO | 28.8yrs |
| Eigendom CEO | 5.0% |
| Management gemiddelde ambtstermijn | 10.9yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$167m |
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$6m | US$880k | US$4m |
Compensatie versus markt: De totale vergoeding ($USD 7.72M ) Jack } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van Jack is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jack Zhang (77 yo)
28.8yrs
Tenure
US$7,722,768
Compensatie
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 28.8yrs | US$3.77m | 2.36% $ 55.4m | |
| Co-founder | 28.8yrs | US$7.72m | 5.01% $ 117.9m | |
| CFO, Executive VP of Finance | 10.5yrs | US$2.89m | 0.075% $ 1.8m | |
| Executive VP of Sales | 11.3yrs | US$1.78m | 0.096% $ 2.2m | |
| Senior EVP of Production & EVP of Scientific Affairs | 9.3yrs | US$2.03m | 0.38% $ 9.0m | |
| Senior Vice President of Human Resources & Corporate Communication | 2.2yrs | geen gegevens | geen gegevens | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | geen gegevens | geen gegevens |
10.9yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AMPH is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 28.8yrs | US$3.77m | 2.36% $ 55.4m | |
| Co-founder | 28.8yrs | US$7.72m | 5.01% $ 117.9m | |
| CFO, Executive VP of Finance | 2.2yrs | US$2.89m | 0.075% $ 1.8m | |
| Executive VP of Sales | 2.2yrs | US$1.78m | 0.096% $ 2.2m | |
| Lead Independent Director | 22.7yrs | US$362.00k | 0.063% $ 1.5m | |
| Independent Director | 3.3yrs | US$330.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.3yrs | US$314.70k | 0.026% $ 620.8k |
5.3yrs
Gemiddelde duur
65.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AMPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).